Does using testosterone help if you are over 50, and can it be dangerous?
Testosterone can be worthwhile for men over 50 with a medically confirmed testosterone deficiency, but it is not a treatment for everyone who is getting older: the benefits are real, the risks are too, and a doctor must establish the indication.
In men over 50 with a medically confirmed testosterone deficiency, testosterone produces measurable benefits. A meta-analysis of 29 studies in men with an average age of 64 found that fat mass decreased by an average of 1.6 kg and muscle mass increased by an average of 1.6 kg. Muscle strength itself improved inconsistently and has not been convincingly demonstrated. Bone density in the lower back increased by 3.7%, but there was no effect at the hip.
The sexual benefits are most strongly supported when you have both low testosterone and low libido. In the large American TRAVERSE trial, involving more than 5,000 men aged 45 to 80, testosterone gel improved sexual activity, desire, and complaints such as fatigue and mood problems. That effect lasted for at least two years. Erectile problems did not improve significantly.
For the heart, TRAVERSE presents a nuanced picture. Heart attacks, strokes, and heart-related deaths occurred equally often in the testosterone and placebo groups: 7.0% versus 7.3%. That is reassuring. However, the testosterone group did experience atrial fibrillation, acute kidney failure, and pulmonary embolism more frequently. These are serious risks that should not be underestimated.
Nuances also apply to the prostate. In TRAVERSE there was no significant difference in prostate cancer diagnoses, although men who already had an elevated risk were excluded beforehand. PSA levels (a blood marker for prostate activity) did rise more in the testosterone group, so regular monitoring is necessary. Notably and still poorly understood: the testosterone group had more bone fractures, even though bone density in the back actually increased.
Testosterone is only supported by evidence for men with a confirmed hormonal disorder, not for everyone whose testosterone declines due to ageing or excess weight. Low testosterone levels are associated in observational studies with higher rates of diabetes, dementia, and premature death, but that does not mean that supplementation also reduces those risks. Use is rising sharply, but a broad preventive application has no scientific basis.
The overall picture rests on a solid foundation: a meta-analysis of 29 randomised studies and the large TRAVERSE trial with more than 5,000 participants. The benefits for body composition and sexuality are fairly convincing. Cardiovascular safety for serious events is reassuring, but the elevated risks of atrial fibrillation, pulmonary embolism, and kidney failure temper that picture. For use in exclusively age-related testosterone decline, the evidence remains weak.